UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Journal of clinical oncology, 2002-05, Vol.20 (10), p.2429-2440

2002

Volltextzugriff (PDF)

Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2002-05, Vol.20 (10), p.2441-2452

2002

Volltextzugriff (PDF)

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

Haematologica (Roma), 2013-09, Vol.98 (9), p.1421-1423

2013

Volltextzugriff (PDF)

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Leukemia research, 2020-07, Vol.94, p.106369-106369, Article 106369

2020

Volltextzugriff (PDF)

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

Leukemia research, 2018-01, Vol.64, p.10-16

2018

Volltextzugriff (PDF)

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Leukemia & lymphoma, 2015-01, Vol.56 (9), p.2543-2551

2015

Volltextzugriff (PDF)

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Blood, 2022-11, Vol.140 (Supplement 1), p.11432-11433

2022

Volltextzugriff (PDF)

An update on the treatment of myelodysplastic syndromes

Clinical journal of oncology nursing, 2010-06, Vol.14 (3), p.E29

2010

Volltextzugriff (PDF)

Treatment of myelodysplastic syndromes: practical tools for effective management

Clinical journal of oncology nursing, 2012-06, Vol.16 Suppl, p.23

2012

Volltextzugriff (PDF)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Blood, 2019-11, Vol.134 (Supplement_1), p.4260-4260

2019

Volltextzugriff (PDF)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Volltextzugriff (PDF)

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Blood, 2021-11, Vol.138 (Supplement 1), p.4325-4325

2021

Volltextzugriff (PDF)

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Blood, 2019-11, Vol.134 (Supplement_1), p.4231-4231

2019

Volltextzugriff (PDF)

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Blood, 2020-11, Vol.136 (Supplement 1), p.35-36

2020

Volltextzugriff (PDF)

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3026-3026

2019

Volltextzugriff (PDF)

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Blood, 2018-11, Vol.132 (Supplement 1), p.5500-5500

2018

Volltextzugriff (PDF)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Blood, 2019-11, Vol.134 (Supplement_1), p.2986-2986

2019

Volltextzugriff (PDF)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Blood, 2017-12, Vol.130, p.4235-4235

2017

Volltextzugriff (PDF)

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Blood, 2015-12, Vol.126 (23), p.1704-1704

2015

Volltextzugriff (PDF)

Advances in myelodysplastic syndrome: nursing implications of azacitidine

Clinical journal of oncology nursing, 2005-08, Vol.9 (4), p.417

2005

Volltextzugriff (PDF)

Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7020-7020

2016

Volltextzugriff (PDF)

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Blood, 2014-12, Vol.124 (21), p.1287-1287

2014

Volltextzugriff (PDF)

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Blood, 2016-12, Vol.128 (22), p.3167-3167

2016

Volltextzugriff (PDF)

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Blood, 2015-12, Vol.126 (23), p.910-910

2015

Volltextzugriff (PDF)

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Blood, 2013-11, Vol.122 (21), p.1527-1527

2013

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(35)
Berichte
(1)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Humans
(8)
Aged
(7)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Male
(6)
Oncology
(6)
Aged, 80 And Over
(5)
Female
(5)
Myelodysplastic Syndromes - Drug Therapy
(5)
Azacitidine - Therapeutic Use
(4)
Hematology
(4)
Middle Aged
(4)
Adult
(3)
Antimetabolites, Antineoplastic - Therapeutic Use
(3)
Myelodysplastic Syndromes
(3)
Nursing
(3)
Treatment Outcome
(3)
Acute Myeloid Leukemia
(2)
Antineoplastic Agents
(2)
Antineoplastic Agents - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(21)
Journal Of Clinical Oncology
(4)
Clinical Journal Of Oncology Nursing
(3)
Leukemia Research
(3)
Cancer Research
(1)
Haematologica
(1)
Leukemia
(1)
Leukemia & Lymphoma
(1)
Leukemia & Lymphoma/leukemia And Lymphoma
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

An update on the treatment of myelodysplastic syndromes

Treatment of myelodysplastic syndromes: practical tools for effective management

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Advances in myelodysplastic syndrome: nursing implications of azacitidine

Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS)

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Suchergebnisse filtern